Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis
Status:
RECRUITING
Trial end date:
2024-12-10
Target enrollment:
Participant gender:
Summary
In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 66 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally.
The study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis.